Amongst health care systems and payers– both federal government and private– this term suggests unnecessary danger to clients, diminished quality of care, and increased health care expenses. From the various research studies and documents released on the topic, a common description emerges: baseless variations are not directly due to the inherent variations of a given client; rather to the variations in the procedures and conditions of how care is provided, particularly when it results in inconsistencies in the adherence to and administering of evidence-based standards of care.
Think about the variations that exist amongst complex disease paths such as oncology.
At the other end of the spectrum is prostate cancer. Although occurrence rates are high, many prostate cancer cases are detected when the cancer is restricted to be within the prostate. Consequently, five-year survival rates are high at approximately 98%in the U.S. and 83%in Europe Small, localized tumors, specific in older guys, are often monitored through an active security procedure. clients frequently go through more aggressive and expensive treatments resulting in unnecessary effects that affect quality of life.
As various as these two oncology paths are, so are the differences in the variations that take place from screening to medical diagnosis and treatment decision to treatment. But what if advances in digitalization and artificial intelligence (AI) techniques could standardize procedures at the crucial actions of diagnosis and treatment decision making? What if providers had support to make diagnostic and healing decisions at these two critical points? And what if service providers could easily access and comply with the current evidence-based standards of care?
Leveraging our experience as a pioneer in AI advancement and our global management in AI patent applications, we at Siemens Healthineers have reacted to these questions by developing digital options that support health care service providers in their diagnostic and therapeutic choice making. These services enable service providers to address variations in care by automating and standardizing processes and facilitating standard adherence.
Created to streamline purchasing choice assistance for proper diagnostic imaging utilization, the Medicalis Medical Decision Assistance makes it simple for referring healthcare service providers to demand imaging assessments with evidence-based support to direct them through “the right order, very first time.”
The AI-Rad Buddy, our growing family of AI-powered, cloud-based enhanced workflows, provides multi-modality and multi-organ imaging decision assistance. The AI-Rad Companion extensions automate workflows and decrease the burden of basic recurring tasks, which might increase diagnostic accuracy when translating medical images. It will be kept in mind that the AI-Rad Companion items and features pointed out are not yet commercially available in all nations. Their future schedule is in the works.
Leveraging data combination and AI techniques, the AI-Pathway Companion, with its applications, allows customized and standardized client management by automating patient-specific mapping along disease-specific care paths using evidence-based standards. A prerequisite to automating patient-specific mapping along disease-specific care pathways utilizing evidence-based guidelines is that all data is available as required per standard. In regards to standards supported, it shall be noted that AI-Pathway Buddy Prostate Cancer VA10 A supports NCCN guidelines. The assistance of EAU standards is currently under development. The AI-Pathway Companion assists in objective decision making by multidisciplinary professionals on correlated client data and choices and provides transparent insights into time to diagnosis and treatment. This particular function is supported by AI-Pathway Companion Analytics.
The amount of the above explained functions is supported by AI-Pathway Companion Prostate Cancer. It will be noted that AI-Pathway Buddy Prostate Cancer supports prostate cancer adenocarcinoma cases just. AI-Pathway Companion Prostate Cancer is not yet commercially available in all nations. Its future accessibility is in the works.
Integrated, our portfolio of diagnostic and healing decision-making digital services enables care-providers to respond to the call to action on minimizing variations in care. Based upon collaborations we are positive clients stand to benefit the most.
Learn more about our portfolio of ordering and clinical decision-making options that support care-providers throughout a client’s illness journey.
